Antibody‐mediated rejection as a contributor to previously unexplained early liver allograft loss

Jacqueline G. O'Leary, Hugo Kaneku, Anthony J. Demetris, John D. Marr, S. Michelle Shiller, Brian M. Susskind, Glenn W. Tillery, Paul I. Terasaki, Göran B. Klintmalm – 6 November 2013 – We analyzed 60 patients with idiopathic early allograft loss (defined as death or retransplantation at <90 days) to determine the relative contribution of preformed donor‐specific human leukocyte antigen alloantibodies (DSAs) to this endpoint, and we defined strict criteria for the diagnosis of antibody‐mediated rejection (AMR) in liver allografts.

Application of complement component 4d immunohistochemistry to ABO‐compatible and ABO‐incompatible liver transplantation

Adeeb Salah, Masakazu Fujimoto, Atsushi Yoshizawa, Kimiko Yurugi, Aya Miyagawa‐Hayashino, Shinji Sumiyoshi, Sachiko Minamiguchi, Shinji Uemoto, Taira Maekawa, Hironori Haga – 6 November 2013 – Antibody‐mediated rejection (AMR) is difficult to diagnose after ABO‐compatible or ABO‐identical (ABO‐C) liver transplantation. To determine whether complement component 4d (C4d) immunostaining would be useful for diagnosing AMR, we compared the results of C4d immunohistochemistry for allograft biopsy samples with assays for anti‐donor antibodies performed at the time of biopsy.

Hepatitis C disease severity in living versus deceased donor liver transplant recipients: An extended observation study

Norah A. Terrault, R. Todd Stravitz, Anna S.F. Lok, Greg T. Everson, Robert S. Brown, Laura M. Kulik, Kim M. Olthoff, Sammy Saab, Ovedele Adeyi, Curtis K. Argo, Jay E. Everhart, Del R. Rodrigo, the A2ALL Study Group – 31 October 2013 – Donor factors influence hepatitis C virus (HCV) disease severity in liver transplant (LT) recipients. Living donors, because they are typically young and have short cold ischemic times, may be advantageous for HCV‐infected patients.

Prerecovery liver biopsy in the brain‐dead donor: A case‐control study of logistics, safety, precision, and utility

Joseph Benton Oliver, Stephen Peters, Advaith Bongu, Abdel‐Kareem Beidas, George Dikdan, Lloyd Brown, Baburao Koneru – 31 October 2013 – Prerecovery liver biopsy (PLB) can potentially to decrease futile recovery and increase utilization of marginal brain‐dead donor (BDD) livers. A case‐control study was conducted to examine the logistics, safety, histological precision, and liver utilization associated with PLB in BDDs. Twenty‐three cases between January 2008 and January 2013 were compared to 2 groups: 48 sequential and 69 clinically matched controls.

Subscribe to